Cellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.com
StockNews.com upgraded shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) to a sell rating in a research report sent to investors on Tuesday. Cellectar Biosciences Stock Performance Cellectar Biosciences stock opened at $2.11 on Tuesday. The firm has a market capitalization of $75.64 million, a P/E ratio of -0.69 and a beta of 0.99. The […]
More Stories
Analysts Set Bausch Health Companies Inc. (NYSE:BHC) Price Target at $7.33
Bausch Health Companies Inc. (NYSE:BHC – Get Free Report) has received a consensus recommendation of “Hold” from the six research...
Albertsons Companies, Inc. (NYSE:ACI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Albertsons Companies, Inc. (NYSE:ACI – Get Free Report) has earned an average rating of “Moderate Buy” from the six brokerages...
Analysts Set D-Wave Quantum Inc. (NYSE:QBTS) Price Target at $2.54
D-Wave Quantum Inc. (NYSE:QBTS – Get Free Report) has received an average rating of “Buy” from the seven research firms...
Darden Restaurants (NYSE:DRI) Releases FY25 Earnings Guidance
Darden Restaurants (NYSE:DRI – Get Free Report) updated its FY25 earnings guidance on Thursday. The company provided earnings per share...
Lawsuit Filed Against Miley Cyrus For Copyright Infringement
American singer-songwriter and actress Miley Cyrus is now facing a legal battle for her song “Flowers,” which won a Grammy...
Michael J. Hartnett Sells 503 Shares of RBC Bearings Incorporated (NYSE:RBC) Stock
RBC Bearings Incorporated (NYSE:RBC – Get Free Report) CEO Michael J. Hartnett sold 503 shares of the company’s stock in...